Endocrinology

Latest News

Dapagliflozin Approved by FDA to Improve Glycemic Control in Children, Adolescents with T2D
Dapagliflozin Approved by FDA to Improve Glycemic Control in Children, Adolescents with T2D

June 19th 2024

Among youth aged 10 to 17 years with uncontrolled hyperglycemia dapagliflozin led to a statistically significant reduction in A1c vs placebo in the T2NOW phase 3 clinical trial.

ADA 84th Scientific Sessions Preview: STEP-HFp-EF Trial Data, Tirzepatide for Obesity-Related OSA, Optimizing Diabetes Care in Primary Care / Image credit: ©Minerva Studio/Shutterstock.com
ADA 84th Scientific Sessions Preview: STEP-HFp-EF Trial Data, Tirzepatide for Obesity-Related OSA, Optimizing Diabetes Care in Primary Care

June 17th 2024

Tirzepatide Superior to Placebo in MASH Resolution, Fibrosis Improvement: Daily Dose / image credit: ©New Africa/AdobeStock
Tirzepatide Superior to Placebo in MASH Resolution, Fibrosis Improvement: Daily Dose

June 17th 2024

Type 1 Diabetes in Older Adults Nearly Tripled in 3 Decades, According to New Data
Type 1 Diabetes in Older Adults Nearly Tripled in 3 Decades, According to New Data

June 14th 2024

Tirzepatide Found Superior to Placebo in MASH Resolution, Fibrosis Improvement
Tirzepatide Found Superior to Placebo in MASH Resolution, Fibrosis Improvement

June 13th 2024

Latest CME Events & Activities

More News

© 2024 MJH Life Sciences

All rights reserved.